Blood Test Before CT Scan to Screen for Lung Cancer
Tests a blood-based screening test before low-dose CT scans in higher-risk adults for lung cancer.
Plain-language title generated from the registry record
Registry title: Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals
Key facts
- Where
- Singapore, SingaporeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 75 years old?
Source: NCT07358715, who can take part
Where in Singapore
- National University Hospital SingaporeSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National University Hospital, Singapore
- Trial code
- NCT07358715
- Record updated
- 22 January 2026
- Original description
This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.Read full original descriptionShow less
A Multimodal Liquid Biopsy-Based Assay as a Pre-Screening Test Before Low Dose CT Thorax (LDCT) to Streamline Lung Cancer Screening in High-Risk Individuals
This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.
Inclusion: High-Risk Individuals (n = 100); No prior history of lung cancer; Meets one of the following high-risk definitions:; Current or former smoker (quit within the past 15 years), aged 55-74 years, with a smoking history of ≥30 pack-years; OR; Never-smoker aged 55-75 years with a first-degree family history of lung cancer; Able and willing to provide written informed consent; Early-Stage Lung Cancer Patients (n = 20); Aged ≥21 years; Histologically or clinically confirmed stage I-II lung cancer; Treatment-naïve (no prior surgery, chemotherapy, radiotherapy, or immunotherapy for lung cancer); Able and willing to provide written informed consent; Advanced-Stage Lung Cancer Patients (n = 20); Aged ≥21 years; Histologically or clinically confirmed stage III-IV lung cancer; Treatment-naïve (no prior systemic or local therapy for lung cancer); Able and willing to provide written informed consent.
Exclusion: Prior low-dose CT (LDCT), CT thorax, or PET-CT performed within 12 months prior to enrollment; Lung Cancer Cohorts Only; Known allergy or contraindication to CT contrast agents; Receipt of any prior cancer-directed treatment for lung cancer; Applicable to All Participants; Pregnant or breastfeeding women; Inability or unwillingness to comply with study procedures; High-Risk Individuals Only.